Vyvanse lisdexamphetamine regulatory update

FDA approved an sNDA from Shire for Vyvanse to treat attention deficit hyperactivity disorder (ADHD) in adults. The prodrug of amphetamine, which is classified as a schedule II controlled substance, i...